Methods: 59 eyes of 38 patients with DME were included in this retrospective study. Based on FFA findings, the patients with DME divided into two groups: the nonischemic DME group and the ischemic DME group. Patients in the nonischemic DME group received ranibizumab monotherapy and patients in the ischemic DME group received a combination therapy including intravitreal injection of ranibizumab and peripheral targeted laser photocoagulation. Mean change in best corrected visual acuity (BCVA), central macular thickness (CMT) and the number of injections were evaluated.

Results: The mean number of injections from baseline to final visit was 5.9±1.4 for the nonischemic DME group and 5.5±1.1 for the ischemic DME group (P=0.451). At the end of the follow-up period, there was no significant difference in terms of CMT reduction and BCVA gain between the two groups.

Conclusion: No significant difference was observed in the need for intravitreal injections between ischemic DME patients treated with laser and non-ischemic DME patients. Keywords : Diabetic macular edema, ranibizumab, peripheral ischemia, laser photocoagulation